The Patent Finder

ProQR Therapeutics II B.V.

18 patents currently held · Updated Nov 22, 2026
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 10, 2027
    The maintenance fee for Targeted RNA editing (US 11,781,134) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
  • 1 fee due Jun 26, 2027
    The maintenance fee for Chemically Modified Single-Stranded RNA-Editing Oligonucleotides (US 11,851,656) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
  • 1 fee due Jul 9, 2027
    The maintenance fee for Nucleic Acid Molecules for Pseudouridylation (US 11,866,702) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
  • 1 fee due Oct 14, 2027
    The maintenance fee for Oligonucleotides to treat eye disease (US 10,617,707) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 24, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,676,737Targeted RNA editing
In force
 · USPTO record
In forceUSPTO record
US 12,655,423Targeted RNA Editing
In force
 · Low confidence
In forceLow confidence
US 10,760,076Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion
In force
 · USPTO record
In forceUSPTO record
US 10,617,707Oligonucleotides to treat eye disease
In force
 · USPTO record
In forceUSPTO record
US 10,988,763Single-Stranded RNA-Editing Oligonucleotides
In force
 · High confidence
In forceHigh confidence
US 11,649,454Single-Stranded RNA-Editing Oligonucleotides
In force
 · Low confidence
In forceLow confidence
US 11,851,656Chemically Modified Single-Stranded RNA-Editing Oligonucleotides
In force
 · High confidence
In forceHigh confidence
US 12,018,257Single-Stranded RNA-Editing Oligonucleotides
In force
 · High confidence
In forceHigh confidence
US 12,203,072Chemically Modified Single-Stranded RNA-Editing Oligonucleotides
In force
 · High confidence
In forceHigh confidence
US 12,545,911Single-Stranded RNA-Editing Oligonucleotides
In force
 · Medium confidence
In forceMedium confidence
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 8 patents in force now held by others · 5 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 14 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited